

## Revvity and Element Biosciences to improve Next Generation Sequencing research workflow

16 October 2023 | News

### Neonatal research applications have been identified as a focus area



American firms Revvity, Inc. and Element Biosciences, Inc., a developer of the AVITI™ System, an innovative and emerging genomic sequencing platform, have announced a collaboration to introduce workflow solutions that save time and effort required for genomic analysis of samples.

Genomic data generated by next generation sequencing (NGS) plays an increasingly important role in scientific innovation and research. The NGS process encompasses a series of detailed steps, including sample collection and processing, nucleic acid extraction, library preparation, quality control, sequencing, data analysis and integration into laboratory information management systems. This process can be daunting, especially for labs that are new to NGS.

Revvity offers carefully curated research use components, spanning the NGS continuum around the sequencing platform. These offerings include sample collection devices, a DBS puncher for punching dried blood spot samples, chemagic™ kits and instruments for automated nucleic acid extraction, a wide range of liquid handlers and reagent kits for automated library preparation, the LabChip® GX Touch HT nucleic acid analyzer and VICTOR2™ D Instrument for sample quality control, and software capabilities that are vital for data management and interpretation.

Earlier this year, Element Biosciences announced a new throughput-based option for its AVITI System that provides the

highest quality sequencing on a benchtop for as low as \$200 a genome, or \$2 per gigabase. Revvity Omics has recently adopted Element's AVITI platform for its global service business, demonstrating improved technology capabilities, flexibility and speed.

Revvity and Element Biosciences plan to make the combined solution available to an expanded customer base interested in the full workflow or specific modules.